Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 879 results found since Jan 2013.
Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer
Oncol Lett. 2022 Mar;23(3):90. doi: 10.3892/ol.2022.13210. Epub 2022 Jan 21.ABSTRACTEnzalutamide is one of the options for treating patients with castration-resistant or metastatic prostate cancer. However, a substantial proportion of patients become resistant to enzalutamide after a period of treatment. Cells in these tumors typically exhibit increased proliferative and migratory capabilities, in which N-cadherin (CDH2) appear to serve an important role. In the present study, by up- and downregulating the expression of CDH2, the possible effects of CDH2 on the prostate cancer cell line LNCaP were investigated. Male sex ho...
Source: Oncology Letters - February 7, 2022 Category: Cancer & Oncology Authors: Cheng-Hsin Lu Chun-Hsien Wu Pei-Fang Hsieh Chen-Yu Wu Wade Wei-Ting Kuo Chien-Hui Ou Victor Chia Hsiang Lin Source Type: research
Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA
In this study, we demonstrated a novel strategy to construct negatively charged and ultrasound (US)-responsive O-carboxymethyl chitosan (O-CMS) NDs as a siRNA targeted delivery system through three-way junction of bacteriophage phi29 DNA packaging motor (3WJ-pRNA) nanotechnology. 39nt A10-3.2 aptamer targeting prostate specific membrane antigen (PSMA) and 21nt siRNA against cationic amino acid transporter 1 (siCAT-1) were annealed to 3WJ-pRNA scaffold via complementation with an extended sequence. The cholesterol molecule attached to one branch facilitates the 3WJ-pRNA nanoparticles anchoring onto NDs. The desired O-CMS ND...
Source: Drug Delivery - January 17, 2022 Category: Drugs & Pharmacology Authors: Lu Guo Dandan Shi Mengmeng Shang Xiao Sun Dong Meng Xinxin Liu Xiaoying Zhou Jie Li Source Type: research
Activation of TGF- β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK
In this study, PCa cells were differentiated with IL-6 in in-vitro to identify novel targets or signaling pathways associated with emergence of NEPC on deprivation of androgens. From the results, we observed an activation of TGF-β signaling pathway is altered through multiple proteins in differentiated LNCaP cells. Hence, we investigated the role of TGF-β axis in PCa cells differentiation. LNCaP cells treated with IL-6 in androgens deprived media release excess TGF-β ligand and this as conditioned media added to cells stimulated NED of PCa cells. TGF-β released by IL-6 stimulated cells activate p38MAPK through SMAD2 th...
Source: Cellular Signalling - January 5, 2022 Category: Cytology Authors: Sirisha Natani K K Sruthi Sakkarai Mohamed Asha Priyanka Khilar Pampana Sandhya Venkata Lakshmi Ramesh Ummanni Source Type: research
Identification and validation of hub genes in prostate cancer progression based on weighted gene co-expression network analysis
CONCLUSION: We identified 3 hub genes related with the occurrence (BDH1, PAK4 and EXTL3) and another 3 with metastasis of prostate cancer (NKTR, CTBP2 and HNRNPA2B1) using WGCNA, which provides a new approach for studying the regulatory mechanisms of prostate cancer.PMID:34916188 | DOI:10.12122/j.issn.1673-4254.2021.11.06
Source: Journal of Southern Medical University - December 17, 2021 Category: Universities & Medical Training Authors: H Zhang N Chen X Wang B Gao M Ling G Chen Z Wu Y Li W Zhong B Pan Source Type: research
